ClearNote Health

ClearNote Health (formerly Bluestar Genomics) is a commercial-stage biotechnology company dedicated to improving early cancer detection through its proprietary epigenomics platform. The company's technology, developed at Stanford University, tracks 5-hydroxymethylcytosine (5hmC) biomarkers and other genomic features in cell-free DNA (cfDNA) to identify cancer signals at their earliest, most treatable stages. By combining biology with artificial intelligence, ClearNote Health provides a comprehensive view of tumor biology to inform patient diagnosis and treatment journeys. The company is initially focused on high-mortality cancers with significant unmet needs, such as pancreatic and ovarian cancer. Its lead product, the Avantect® Pancreatic Cancer Test, is designed for high-risk populations, including individuals recently diagnosed with Type 2 diabetes. ClearNote Health operates a CAP-accredited, CLIA-certified laboratory in San Diego and is expanding its global reach through strategic partnerships in Asia and Europe.